Antibe Therapeutics (Antibe Therapeutics) Gross-Profit-to-Asset % : 0.00% (As of Dec. 2023)

View and export this data going back to 2014. Start your Free Trial

What is Antibe Therapeutics Gross-Profit-to-Asset %?

Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. Antibe Therapeutics's annualized Gross Profit for the quarter that ended in Dec. 2023 was $0.00 Mil. Antibe Therapeutics's average Total Assets over the quarter that ended in Dec. 2023 was $43.25 Mil. Therefore, Antibe Therapeutics's annualized Gross-Profit-to-Asset % for the quarter that ended in Dec. 2023 was 0.00%.

Antibe Therapeutics Gross-Profit-to-Asset % Historical Data

The historical data trend for Antibe Therapeutics's Gross-Profit-to-Asset % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Antibe Therapeutics Gross-Profit-to-Asset % Chart

Antibe Therapeutics Annual Data

Trend

Mar14

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Gross-Profit-to-Asset %

Get a 7-Day Free Trial

25.60

25.22

7.54

Antibe Therapeutics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Gross-Profit-to-Asset %	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Antibe Therapeutics's Gross-Profit-to-Asset %

For the Biotechnology subindustry, Antibe Therapeutics's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Antibe Therapeutics's Gross-Profit-to-Asset % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Antibe Therapeutics's Gross-Profit-to-Asset % distribution charts can be found below:

* The bar in red indicates where Antibe Therapeutics's Gross-Profit-to-Asset % falls into.

Antibe Therapeutics Gross-Profit-to-Asset % Calculation

Antibe Therapeutics's annualized Gross-Profit-to-Asset % for the fiscal year that ended in Mar. 2023 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (A: Mar. 2023 )	/	( (Total Assets (A: Mar. 2022 )	+	Total Assets (A: Mar. 2023 ))	/ count )
	=	0	/	( (70.425	+	51.568)	/ 2 )
	=	0	/	60.9965
	=	0.00 %

Antibe Therapeutics's annualized Gross-Profit-to-Asset % for the quarter that ended in Dec. 2023 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (Q: Dec. 2023 )	/	( (Total Assets (Q: Sep. 2023 )	+	Total Assets (Q: Dec. 2023 ))	/ count )
	=	0	/	( (44.494	+	42.011)	/ 2 )
	=	0	/	43.2525
	=	0.00 %

In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Gross Profit data used here is four times the quarterly (Dec. 2023) data. Gross-Profit-to-Asset % is displayed in the 30-year financial page.

Antibe Therapeutics Gross-Profit-to-Asset % Related Terms

Thank you for viewing the detailed overview of Antibe Therapeutics's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.

Antibe Therapeutics (Antibe Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Antibe Therapeutics Inc (OTCPK:ATBPF) » Definitions » Gross-Profit-to-Asset %

Comparable Companies

Traded in Other Exchanges

ATE:Canada

Address

15 Prince Arthur Avenue, Toronto, ON, CAN, M5R 1B2

Website

https://www.antibethera.com

Antibe Therapeutics Inc is leveraging its proprietary hydrogen sulfide platform to develop next-generation safer therapies to target inflammation arising from a wide range of medical conditions. The company's pipeline includes assets that seek to overcome gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs. Antibe's lead drug, otenaproxesul, is in clinical development as a safer alternative to opioids for post-operative pain. Antibe's second pipeline drug, ATB-352, is being developed for a specialized acute pain indication. The company's anticipated next target is inflammatory bowel disease, a condition long in need of safer, more effective therapies.